相关实验视频

Updated: Jun 18, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

针对肺癌的PD-1/PD-L1和CTLA-4的双阻塞免疫疗法

Weishi Cheng¹, Kai Kang^2,3, Ailin Zhao⁴

¹Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

Journal of hematology & oncology

|July 27, 2024

概括

结合PD-1/PD-L1和CTLA-4抑制剂的双阻塞免疫疗法在肺癌中显示出有前途. 这种方法可以增强免疫反应,但需要仔细管理潜在的副作用.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

免疫检查点抑制剂 (ICI),如抗PD-1/PD-L1和抗CTLA-4,已经改变了肺癌的治疗.
单一治疗ICI可能会出现耐药性和有效性有限.
针对PD-1/PD-L1和CTLA-4的双重阻断提供了针对癌细胞的协同免疫激活.

研究的目的:

审查双阻塞免疫疗法 (抗PD-1/PD-L1和抗CTLA-4) 在肺癌中的作用和机制.
总结目前临床试验的进展,并讨论潜在的组合策略.
探索双特异性抗体如何改善双重ICI的疗效和安全性.

主要方法:

对肺癌中双重ICI治疗的临床前研究和临床试验的文献综述.
对协同免疫反应背后的机制的分析.
评估与组合疗法相关的安全性概况和不良事件.

主要成果:

与单一治疗相比,双阻塞免疫疗法显示出增强的抗瘤免疫反应.
临床试验显示了潜在的疗效,但也强调了与免疫相关的不良事件的发生率.
双特异性抗体为同时向提供了一个有希望的途径,可能减轻毒性.

结论:

针对PD-1/PD-L1和CTLA-4的双阻塞免疫疗法是肺癌治疗的有希望的策略.
需要进一步的研究和临床试验来优化组合疗法和管理不良事件.
双特异性抗体技术可能会提高肺癌中双重ICI策略的治疗指数.

关键词:

生物标志物生物标志物双特异性抗体双特异性抗体组合疗法是一种联合疗法.免疫检查点抑制剂免疫检查点抑制剂肺癌是一种肺癌.

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...